Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583270 | 0.88 | KDM4E (0.64) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL5204247 | 0.86 | KDM4E (0.61) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL12837985 | 0.83 | KDM4E (0.58) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL15265840 | 0.82 | CA12 (0.53) | KDM4EKMT2AMEN1CA12CA1 | |
| SCHEMBL30014968 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL583987 | 0.81 | ALDH1A1 (0.79) | KDM4EALDH1A1KMT2AHPGDCA12 | |
| SCHEMBL1620578 | 0.81 | ALDH1A1 (0.79) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL9288795 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL20488880 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL20488853 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1KMT2AHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250250264-A1 | KIF18A INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-08-07 | — | — | US | disclosed |
| US-20250223300-A1 | MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BETTA PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4559920-A1 | MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2025-05-28 | — | — | EP | disclosed |
| US-20250147039-A1 | Compounds for complexation of rare earth elements and/or s-, p-, d- block metals, their coordination compounds, peptide conjugates, method of their preparation and use thereof | Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) | 2025-05-08 | — | — | US | disclosed |
| CN-119731177-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4509505-A1 | KIF18A INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034165-A1 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4377308-B1 | COMPOUNDS FOR COMPLEXATION OF RARE EARTH ELEMENTS AND/OR S-, P-, D- BLOCK METALS, THEIR COORDINATION COMPOUNDS, PEPTIDE CONJUGATES, METHOD OF THEIR PREPARATION AND USE THEREOF | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2024-11-20 | — | — | EP | disclosed |
| EP-4442690-A1 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| US-20110086846-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-7879873-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-7879873-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-7879873-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086846-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | KDM4E 2535/4885ALDH1A1 523/4885KMT2A 2845/4885 |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | KDM4E 2535/4885ALDH1A1 523/4885KMT2A 2845/4885 |
| US-20250147039-A1 | Compounds for complexation of rare earth elements and/or s-, p-, d- block metals, their coordination compounds, peptide conjugates, method of their preparation and use thereof | SCLY, CD79B, CSTB | KDM4E 4829/4885ALDH1A1 4360/4885KMT2A 4604/4885 |
| US-20250223300-A1 | MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | EGFR, ERBB3, ERBB2 | KDM4E 2994/4885ALDH1A1 3526/4885KMT2A 3995/4885 |
| US-20250250264-A1 | KIF18A INHIBITOR AND USE THEREOF | KIF18A, KIF18B, KIF15 | KDM4E 1075/4885ALDH1A1 1345/4885KMT2A 141/4885 |
| US-20250034165-A1 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | KRAS, HRAS, VHL | KDM4E 4088/4885ALDH1A1 1265/4885KMT2A 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.